메뉴 건너뛰기




Volumn 359, Issue 2, 2016, Pages 280-289

Renal effects of antisense-mediated inhibition of SGLT2

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANTISENSE OLIGONUCLEOTIDE; BETA 2 MICROGLOBULIN; CREATININE; GLUCOSE; GLUTATHIONE TRANSFERASE; ISIS 388626; KIDNEY INJURY MOLECULE 1; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG; OLIGODEOXYRIBONUCLEOTIDE;

EID: 84990929280     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.233809     Document Type: Article
Times cited : (18)

References (40)
  • 1
    • 0032861050 scopus 로고    scopus 로고
    • A rise in plasma creatinine that is not a sign of renal failure: Which drugs can be responsible?
    • Andreev E, Koopman M, and Arisz L (1999) A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 246:247-252.
    • (1999) J Intern Med , vol.246 , pp. 247-252
    • Andreev, E.1    Koopman, M.2    Arisz, L.3
  • 4
    • 84893844270 scopus 로고    scopus 로고
    • Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
    • Cefalu WT (2014) Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 124:485-487.
    • (2014) J Clin Invest , vol.124 , pp. 485-487
    • Cefalu, W.T.1
  • 5
    • 84941844370 scopus 로고
    • Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat
    • Feinfeld DA, Fuh VL, and Safirstein R (1986) Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat. J Clin Chem Clin Biochem 24:529-532.
    • (1986) J Clin Chem Clin Biochem , vol.24 , pp. 529-532
    • Feinfeld, D.A.1    Fuh, V.L.2    Safirstein, R.3
  • 7
    • 8344257283 scopus 로고    scopus 로고
    • A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria
    • Francis J, Zhang J, Farhi A, Carey H, and Geller DS (2004) A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 19:2893-2895.
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 2893-2895
    • Francis, J.1    Zhang, J.2    Farhi, A.3    Carey, H.4    Geller, D.S.5
  • 8
    • 84903639158 scopus 로고    scopus 로고
    • Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide
    • Frazier KS, Sobry C, Derr V, Adams MJ, Besten CD, Kimpe SD, Francis I, Gales TL, Haworth R, Maguire SR, et al. (2013) Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol 42:923-935.
    • (2013) Toxicol Pathol , vol.42 , pp. 923-935
    • Frazier, K.S.1    Sobry, C.2    Derr, V.3    Adams, M.J.4    Besten, C.D.5    Kimpe, S.D.6    Francis, I.7    Gales, T.L.8    Haworth, R.9    Maguire, S.R.10
  • 10
    • 0030918233 scopus 로고    scopus 로고
    • Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
    • Henry SP, Bolte H, Auletta C, and Kornbrust DJ (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120:145-155.
    • (1997) Toxicology , vol.120 , pp. 145-155
    • Henry, S.P.1    Bolte, H.2    Auletta, C.3    Kornbrust, D.J.4
  • 11
    • 84864811592 scopus 로고    scopus 로고
    • Renal uptake and tolerability of a 29-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey
    • Henry SP, Johnson M, Zanardi TA, Fey R, Auyeung D, Lappin PB, and Levin AA (2012) Renal uptake and tolerability of a 29-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology 301:13-20.
    • (2012) Toxicology , vol.301 , pp. 13-20
    • Henry, S.P.1    Johnson, M.2    Zanardi, T.A.3    Fey, R.4    Auyeung, D.5    Lappin, P.B.6    Levin, A.A.7
  • 12
    • 78751632457 scopus 로고    scopus 로고
    • Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma
    • Herrington WG, Talbot DC, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, and Roberts IS (2011) Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis 57:300-303.
    • (2011) Am J Kidney Dis , vol.57 , pp. 300-303
    • Herrington, W.G.1    Talbot, D.C.2    Lahn, M.M.3    Brandt, J.T.4    Callies, S.5    Nagle, R.6    Winearls, C.G.7    Roberts, I.S.8
  • 15
    • 84911492396 scopus 로고    scopus 로고
    • Empagliflozin for the treatment of type 2 diabetes
    • Jahagirdar V and Barnett AH (2014) Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 15:2429-2441.
    • (2014) Expert Opin Pharmacother , vol.15 , pp. 2429-2441
    • Jahagirdar, V.1    Barnett, A.H.2
  • 16
    • 84891878819 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2
    • Kasichayanula S, Liu X, Lacreta F, Griffen SC, and Boulton DW (2014) Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53:17-27
    • (2014) Clin Pharmacokinet , vol.53 , pp. 17-27
    • Kasichayanula, S.1    Liu, X.2    Lacreta, F.3    Griffen, S.C.4    Boulton, D.W.5
  • 17
    • 33750207033 scopus 로고    scopus 로고
    • Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    • Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, and Crooke RM (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114:1729-1735.
    • (2006) Circulation , vol.114 , pp. 1729-1735
    • Kastelein, J.J.1    Wedel, M.K.2    Baker, B.F.3    Su, J.4    Bradley, J.D.5    Yu, R.Z.6    Chuang, E.7    Graham, M.J.8    Crooke, R.M.9
  • 18
    • 84863259511 scopus 로고    scopus 로고
    • An overview of clinical safety experience of first- and second-generation antisense oligonucleotides
    • (Crooke ST ed) CRC Press, Boca Raton, FL
    • Kwoh TJ (2007) An overview of clinical safety experience of first- and second-generation antisense oligonucleotides, in Antisense Drug Technology: Principles, Strategies, and Application (Crooke ST ed), 365-399, CRC Press, Boca Raton, FL.
    • (2007) Antisense Drug Technology: Principles, Strategies, and Application , pp. 365-399
    • Kwoh, T.J.1
  • 19
    • 0033574249 scopus 로고    scopus 로고
    • A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
    • Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, and Roth D; Modification of Diet in Renal Disease Study Group (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470.
    • (1999) Ann Intern Med , vol.130 , pp. 461-470
    • Levey, A.S.1    Bosch, J.P.2    Lewis, J.B.3    Greene, T.4    Rogers, N.5    Roth, D.6
  • 20
    • 84925283858 scopus 로고    scopus 로고
    • CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
    • Limmroth V, Barkhof F, Desem N, Diamond MP, and Tachas G; ATL1102 Study Group (2014) CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 83:1780-1788.
    • (2014) Neurology , vol.83 , pp. 1780-1788
    • Limmroth, V.1    Barkhof, F.2    Desem, N.3    Diamond, M.P.4    Tachas, G.5
  • 21
    • 0014844684 scopus 로고
    • Automated simultaneous determination of p-acetylaminohippurate and inulin in serum
    • Looyé A (1970) Automated simultaneous determination of p-acetylaminohippurate and inulin in serum. Clin Chem 16:753-755.
    • (1970) Clin Chem , vol.16 , pp. 753-755
    • Looyé, A.1
  • 24
    • 84869072637 scopus 로고    scopus 로고
    • Urinary N-acetyl-b-D-glucosaminidase levels are positively correlated with 2-hr plasma glucose levels during oral glucose tolerance testing in prediabetes
    • Ouchi M, Suzuki T, Hashimoto M, Motoyama M, Ohara M, Suzuki K, Igari Y, Watanabe K, Nakano H, and Oba K (2012) Urinary N-acetyl-b-D-glucosaminidase levels are positively correlated with 2-hr plasma glucose levels during oral glucose tolerance testing in prediabetes. J Clin Lab Anal 26:473-480.
    • (2012) J Clin Lab Anal , vol.26 , pp. 473-480
    • Ouchi, M.1    Suzuki, T.2    Hashimoto, M.3    Motoyama, M.4    Ohara, M.5    Suzuki, K.6    Igari, Y.7    Watanabe, K.8    Nakano, H.9    Oba, K.10
  • 25
    • 84869998632 scopus 로고    scopus 로고
    • Dapagliflozin: A review of its use in type 2 diabetes mellitus
    • Plosker GL (2012) Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 72:2289-2312.
    • (2012) Drugs , vol.72 , pp. 2289-2312
    • Plosker, G.L.1
  • 29
    • 84924415690 scopus 로고    scopus 로고
    • Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
    • Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, and Mittleman RS (2013) Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 36:566-575.
    • (2013) Eur Heart J , vol.36 , pp. 566-575
    • Santos, R.D.1    Duell, P.B.2    East, C.3    Guyton, J.R.4    Moriarty, P.M.5    Chin, W.6    Mittleman, R.S.7
  • 30
    • 84918546698 scopus 로고    scopus 로고
    • Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
    • Scheen AJ and Paquot N (2014) Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab 40(6, Suppl 1): S4-S11.
    • (2014) Diabetes Metab , vol.40 , Issue.6 , pp. S4-S11
    • Scheen, A.J.1    Paquot, N.2
  • 32
    • 84860238875 scopus 로고    scopus 로고
    • Nephrotoxicity of hexachloro-1:3-butadiene in the male hanover wistar rat; correlation of minimal histopathological changes with biomarkers of renal injury
    • Swain A, Turton J, Scudamore C, Maguire D, Pereira I, Freitas S, Smyth R, Munday M, Stamp C, Gandhi M, et al. (2012) Nephrotoxicity of hexachloro-1:3-butadiene in the male Hanover Wistar rat; correlation of minimal histopathological changes with biomarkers of renal injury. J Appl Toxicol 32:417-428.
    • (2012) J Appl Toxicol , vol.32 , pp. 417-428
    • Swain, A.1    Turton, J.2    Scudamore, C.3    Maguire, D.4    Pereira, I.5    Freitas, S.6    Smyth, R.7    Munday, M.8    Stamp, C.9    Gandhi, M.10
  • 33
    • 0029618259 scopus 로고
    • Conventional measurement of renal function utilizing serum creat-inine, creatinine clearance, inulin and para-aminohippuric acid clearance
    • discussion 503-504
    • Toto RD (1995) Conventional measurement of renal function utilizing serum creat-inine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens 4:505-509, discussion 503-504
    • (1995) Curr Opin Nephrol Hypertens , vol.4 , pp. 505-509
    • Toto, R.D.1
  • 37
    • 84901359283 scopus 로고    scopus 로고
    • Urinary kidney bio-markers for early detection of nephrotoxicity in clinical drug development
    • van Meer L, Moerland M, Cohen AF, and Burggraaf J (2014) Urinary kidney bio-markers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol 77:947-957.
    • (2014) Br J Clin Pharmacol , vol.77 , pp. 947-957
    • Van Meer, L.1    Moerland, M.2    Cohen, A.F.3    Burggraaf, J.4
  • 39
    • 0016153194 scopus 로고
    • Simplified measurement of p-aminohippurate and other arylamines in plasma and urine
    • Waugh WH and Beall PT (1974) Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. Kidney Int 5:429-436.
    • (1974) Kidney Int , vol.5 , pp. 429-436
    • Waugh, W.H.1    Beall, P.T.2
  • 40
    • 84867619259 scopus 로고    scopus 로고
    • Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second generation antisense oligonucleotide that targets the human sodium glucose cotransporter 2 (SGLT2)
    • Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, and Henry SP (2012) Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second generation antisense oligonucleotide that targets the human sodium glucose cotransporter 2 (SGLT2). J Pharmacol Exp Ther 343:489-496
    • (2012) J Pharmacol Exp Ther , vol.343 , pp. 489-496
    • Zanardi, T.A.1    Han, S.C.2    Jeong, E.J.3    Rime, S.4    Yu, R.Z.5    Chakravarty, K.6    Henry, S.P.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.